ARTL
Price
$5.49
Change
-$0.07 (-1.26%)
Updated
Sep 26, 04:57 PM (EDT)
Capitalization
10.91M
FATE
Price
$0.99
Change
+$0.02 (+2.06%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
111.96M
34 days until earnings call
Interact to see
Advertisement

ARTL vs FATE

Header iconARTL vs FATE Comparison
Open Charts ARTL vs FATEBanner chart's image
Artelo Biosciences
Price$5.49
Change-$0.07 (-1.26%)
Volume$100
Capitalization10.91M
Fate Therapeutics
Price$0.99
Change+$0.02 (+2.06%)
Volume$19.4K
Capitalization111.96M
ARTL vs FATE Comparison Chart in %
Loading...
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTL vs. FATE commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Hold and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ARTL: $5.56 vs. FATE: $0.97)
Brand notoriety: ARTL and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 35% vs. FATE: 86%
Market capitalization -- ARTL: $10.91M vs. FATE: $111.96M
ARTL [@Biotechnology] is valued at $10.91M. FATE’s [@Biotechnology] market capitalization is $111.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ARTL’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ARTL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • ARTL’s TA Score: 5 bullish, 3 bearish.
  • FATE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ARTL is a better buy in the short-term than FATE.

Price Growth

ARTL (@Biotechnology) experienced а 0.00% price change this week, while FATE (@Biotechnology) price change was -2.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +52.01%.

Reported Earning Dates

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($112M) has a higher market cap than ARTL($10.9M). ARTL YTD gains are higher at: -12.579 vs. FATE (-41.164). ARTL has higher annual earnings (EBITDA): -10.71M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. ARTL (2.07M). ARTL has less debt than FATE: ARTL (878K) vs FATE (81.3M). FATE has higher revenues than ARTL: FATE (8.47M) vs ARTL (0).
ARTLFATEARTL / FATE
Capitalization10.9M112M10%
EBITDA-10.71M-161.6M7%
Gain YTD-12.579-41.16431%
P/E RatioN/AN/A-
Revenue08.47M-
Total Cash2.07M223M1%
Total Debt878K81.3M1%
FUNDAMENTALS RATINGS
ARTL vs FATE: Fundamental Ratings
ARTL
FATE
OUTLOOK RATING
1..100
1062
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for ARTL (60) in the null industry. This means that FATE’s stock grew somewhat faster than ARTL’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

FATE's Price Growth Rating (64) in the Biotechnology industry is in the same range as ARTL (65) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZAIRF0.03N/A
+4.73%
ABOUND ENERGY INC.
FLRAF1.24N/A
N/A
Essentra PLC
HPHTY5.84N/A
N/A
Hamamatsu Photonics
MSSAF11.79N/A
N/A
Metal Sky Star Acquisition Corporation
IFJPY24.55-0.31
-1.26%
Informa Plc.

ARTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARTL has been loosely correlated with NEVPF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTL jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTL
1D Price
Change %
ARTL100%
-2.46%
NEVPF - ARTL
35%
Loosely correlated
N/A
PALI - ARTL
34%
Loosely correlated
+12.95%
CRMD - ARTL
32%
Poorly correlated
-1.07%
FATE - ARTL
31%
Poorly correlated
-3.88%
IGC - ARTL
30%
Poorly correlated
-4.38%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-3.88%
RXRX - FATE
53%
Loosely correlated
-5.12%
CRBU - FATE
53%
Loosely correlated
-9.39%
ALLO - FATE
51%
Loosely correlated
-2.44%
IPSC - FATE
50%
Loosely correlated
+0.66%
MGNX - FATE
50%
Loosely correlated
-4.07%
More